Skip to main content

 Scientific publications

The 2019 World Health Organization classification of tumours of the breast.

Authors : Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, Sapino A, Sasano H, Schnitt S, Sotiriou C, van Diest P, White VA, Lokuhetty D, Cree IA
Year : 2020
Journal : Histopathology
Volume : 77
Pages : 181-185

Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.

Authors : Sonnenblick A, Salmon-Divon M, Salgado R, Dvash E, Pondé N, Zahavi T, Salmon A, Loibl S, Denkert C, Joensuu H, Ameye L, Van den Eynden G, Kellokumpu-Lehtinen PL, Azaria A, Loi S, Michiels S, Richard F, Sotiriou C
Year : 2020
Journal : Int J Cancer
Volume : 147
Pages : 266-276

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.

Authors : Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart M, Sotiriou C, Jamieson SMF
Year : 2020
Journal : Br J Cancer
Volume : 122
Pages : 603-612

Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.

Authors : Caparica R, Richard F, Brandão M, Awada A, Sotiriou C, de Azambuja E
Year : 2020
Journal : Clin Breast Cancer
Volume : 20
Pages : 262-273.e7

Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.

Authors : Richard F, Majjaj S, Venet D, Rothé F, Pingitore J, Boeckx B, Marchio C, Clatot F, Bertucci F, Mariani O, Galant C, Eynden GVD, Salgado R, Biganzoli E, Lambrechts D, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C, Desmedt C
Year : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 6254-6265

Digital analysis of distant and cancer-associated mammary adipocytes.

Authors : Isnaldi E, Richard F, De Schepper M, Vincent D, Leduc S, Maetens M, Geukens T, Floris G, Rouas G, Cardoso F, Sotiriou C, Zoppoli G, Larsimont D, Biganzoli E, Desmedt C
Year : 2020
Journal : Breast
Volume : 54
Pages : 179-186

PD-1 protein and gene expression as prognostic factors in early breast cancer.

Authors : Matikas A, Zerdes I, Lövrot J, Sifakis E, Richard F, Sotiriou C, Rassidakis G, Bergh J, Valachis A, Foukakis T
Year : 2020
Journal : ESMO Open
Volume : 5

Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.

Authors : Gómez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernández-Jiménez E, Maetens M, Salgado R, Zafeiroglou M, Pellegrini P, Venet D, Garaud S, Trinidad EM, Benítez S, Vuylsteke P, Polastro L, Wildiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothé F, Willard-Gallo K, Michiels S, Muñoz P, Walzer T, Planelles L, Penninger J, Azim HA Jr, Loi S, Piccart-Gebhart M, Sotiriou C, González-Suárez E
Year : 2020
Journal : Nat Commun
Volume : 11
Pages : 6335

Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients.

Authors : Bohlok A, Vermeulen P, Leduc S, Latacz E, Botzenhart L, Richard F, De Schepper M, Geukens T, Lucidi V, Ignatiadis M, Aftimos P, Sotiriou C, Piccart-Gebhart M, Hendlisz A, Van Laere S, Dirix L, Noël JC, Biganzoli E, Larsimont D, Desmedt C, Donckier V
Year : 2020
Journal : NPJ Breast Cancer
Volume : 6
Pages : 64

Pan-cancer analysis of whole genomes.

Authors : Campbell PJ, Sotiriou C, Larsimont D, et al.
Year : 2020
Journal : Nature
Volume : 578
Pages : 82-93

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Authors : Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C
Year : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 69-77

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Authors : Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Year : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 1434

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

Authors : Nguyen B, Venet D, Lambertini M, Desmedt C, Salgado R, Horlings HM, Rothé F, Sotiriou C
Year : 2019
Journal : Breast Cancer Res
Volume : 21
Pages : 25

pAKT pathway activation is associated with <i>PIK3CA</i> mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation.

Authors : Sonnenblick A, Venet D, Brohée S, Pondé N, Sotiriou C
Year : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 7

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Authors : Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 365-373

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Authors : Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, OMeara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, vant Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, Van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR
Year : 2019
Journal : Nature

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Authors : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1018

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Authors : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1180

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Authors : Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart-Gebhart M, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S
Year : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 559-569

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.

Authors : Lan Q, Peyvandi S, Duffey N, Huang YT, Barras D, Held W, Richard F, Delorenzi M, Sotiriou C, Desmedt C, Lorusso G, Rüegg C
Year : 2019
Journal : Oncogene
Volume : 38
Pages : 2814-2829